8.05
-0.7(-8.00%)
Currency In USD
| Previous Close | 8.75 |
| Open | 8.78 |
| Day High | 8.78 |
| Day Low | 8 |
| 52-Week High | 1,200 |
| 52-Week Low | 8 |
| Volume | 125,918 |
| Average Volume | 146,529 |
| Market Cap | 60.83M |
| PE | -0.3 |
| EPS | -26.4 |
| Moving Average 50 Days | 113.34 |
| Moving Average 200 Days | 328.48 |
| Change | -0.7 |
If you invested $1000 in Helius Medical Technologies, Inc. (HSDT) 10 years ago, it would be worth $0 as of July 12, 2025 at a share price of $8.05. Whereas If you bought $1000 worth of Helius Medical Technologies, Inc. (HSDT) shares 5 years ago, it would be worth $0.01 as of July 12, 2025 at a share price of $8.05.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Helius Medical Technologies, Inc. Compliant with Nasdaq’s Continued Listing Requirements
GlobeNewswire Inc.
Jul 09, 2025 12:30 PM GMT
NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, toda
Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device
GlobeNewswire Inc.
Jun 16, 2025 11:00 AM GMT
- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
GlobeNewswire Inc.
Jun 12, 2025 11:00 AM GMT
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line